Investor relations

Why invest in Coegin Pharma?

Coegin Pharma has an experienced management team and board of directors with strong expertise in drug development, commercialization, business development and financing. The company possesses two unique technology platforms with great therapeutic potential for the treatment of inflammatory driven cancers and diabetes complications.

Through the acquisition of Follicum AB (“Follicum”) and the positive results from the COAK study, Coegin Pharma has established a broader and more mature project pipeline. The company is ready to take the next step on the journey towards creating long-term values ​​through a number of unique projects, solid competencies in combination with a limited capital requirement.

Through separate portfolio companies, Coegin Pharma will develop and value well-validated development projects. Coegin Pharma intends to actively broaden the project portfolio in the company's existing unique technologies and external acquisitions. Common to the projects is that they must have a well-validated research basis, attractive commercial conditions, potential for early exit and a clear opportunity for Coegin Pharma to value the project. At the same time, the company must be active in its exit work for each portfolio company.

This combined with Coegin Pharma's competencies and platform that creates the right conditions for increased growth and value added without significantly accelerating Coegin Pharma's financial risk and capital needs.

“We are ready to exploit the therapeutic potential of our platform to develop drugs for several indications where the need for new treatments is high.”

- Tore Duvold

Financial Calendar

November 24 2022
Interim report Q3 2022
February 27 2023
Year end report 2022

Latest reports

IR Contact